7 results about "Echinococcosis" patented technology

The invention relates to a gene marker group, a primer, a kit and application of the gene marker group, the primer and the kit in detection of echinococcosis, and belongs to the technical field of biology. Wherein the gene marker group comprises at least one of (c1) to (c230). The gene marker group can be used for designing multiple detection primers for detecting echinococcus.

The invention discloses an echinococcus multilocularis monoclonal antibody and a fluorescent microsphere immunochromatography detection test strip, and relates to the technical field of monoclonal antibodies. The echinococcus multilocularis monoclonal antibody is an echinococcus multilocularis monoclonal antibody 13H11F4, the amino acid sequence of a heavy chain of the echinococcus multilocularis monoclonal antibody is shown as SEQ ID NO.1, and the amino acid sequence of a light chain of the echinococcus multilocularis monoclonal antibody is shown as SEQ ID NO.2. The monoclonal antibody 13H11F4 of the echinococcus multilocularis can be combined with other monoclonal antibodies of the echinococcus multilocularis, so that the echinococcus multilocularis can be detected by a double-antibody sandwich method. The fluorescent microsphere immunochromatography test strip prepared from 13H11F4 and other monoclonal antibodies of other echinococcosis multilocularis is used for medical detection of echinococcosis multilocularis, has the advantages of high sensitivity, short reaction time, strong anti-interference capability and accurate and reliable detection result, and has wide clinical application value.

This invention belongs to the field of food enzyme engineering technology, specifically relating to a strain of *Aspergillus echinococcosis* that produces highly efficient ester-degrading catechin tannin enzymes and its applications. The strain is classified as *Aspergillus echinococcosis* (…). Aspergillus aculeatus LS06, with accession number CGMCC No. 42170. The *Aspergillus echinococcosis* strain provided by this invention serves as a tannin-producing strain, using inexpensive agricultural waste bran as raw material, resulting in low production costs. Simultaneously, the produced tannins exhibit high enzyme activity and high catalytic efficiency for ester-type catechins, demonstrating promising application prospects in tea beverage processing.

The invention discloses a novel anti-echinococcus monoclonal antibody, a hybridoma cell strain and application of the novel anti-echinococcus monoclonal antibody, and belongs to the technical field of biomedicine and immunology. The preservation number of the hybridoma cell strain Anti-Em-11 disclosed by the invention is CGMCC (China General Microbiological Culture Collection Center) No. 46598. According to the present invention, the specific monoclonal antibody is successfully prepared and identified, and Western blot and indirect immunofluorescence experiments prove that the obtained monoclonal antibody has high specificity on the recombinant protein. The invention lays a solid foundation for serological diagnosis of the echinococcosis and remarkably enriches the existing serological detection technical system.

This invention discloses a multilocular echinococcosis larva. In Preparation method of -6B protein and its application in the preparation of anti-host inflammatory agents. Through protein structure modeling and molecular docking technology, the preparation method was confirmed. In -6B can bind with high affinity to a key subunit of the host 26S proteasome, affecting the assembly of the proteasome in the host and thus interfering with the activity of the NF-κB signaling pathway, thereby regulating the host inflammatory response. Animal experiments have shown that recombinant... In -6B intervention significantly alleviated colonic damage in mice with inflammatory bowel disease, regulated the expression levels of pro-inflammatory and anti-inflammatory factors, and improved the survival rate of septic mice, with no obvious toxic side effects observed. This invention opens up a new pathway for developing anti-inflammatory agents using natural molecules that interact with the parasite's immune system, and provides a novel mechanism of action and biosafety for anti-host inflammatory biological agents, showing great potential for application in the prevention and treatment of inflammatory diseases in humans and livestock.

The invention discloses an echinococcus multilocularis monoclonal antibody and a fluorescent microsphere immunochromatography detection test strip, and relates to the technical field of monoclonal antibodies. The echinococcus multilocularis monoclonal antibody is an echinococcus multilocularis monoclonal antibody 2G7C3, the amino acid sequence of a heavy chain of the echinococcus multilocularis monoclonal antibody 2G7C3 is shown as SEQ ID NO.1, and the amino acid sequence of a light chain of the echinococcus multilocularis monoclonal antibody 2G7C3 is shown as SEQ ID The echinococcosis multilocularis monoclonal antibody 2G7C3 can be combined with other monoclonal antibodies of echinococcosis multilocularis, so that the echinococcosis multilocularis can be detected by a double-antibody sandwich method. The fluorescent microsphere immunochromatography test strip prepared from 2G7C3 and other monoclonal antibodies of other echinococcosis multilocularis is used for medical detection of echinococcosis multilocularis, has the advantages of high sensitivity, short reaction time, strong anti-interference capability and accurate and reliable detection result, and has wide clinical application value.

The invention relates to the technical field of gene inhibitors, in particular to an inhibitor of a targeted macrophage UPF3B gene and application of the inhibitor in preparation of drugs for preventing or / and treating echinococcosis granulosa. In particular to siRNA capable of inhibiting the activity of macrophage UPF3B, blocking gene transcription of the macrophage or reducing the expression level of the macrophage UPF3B; the inhibitor can be used for knocking down the expression of a macrophage UPF3B gene in a macrophage model (simulating the pathophysiological process of echinococcosis granulosus) stimulated by cyst fluid of echinococcosis granulosus, regulating an AKT signal in the macrophage and inhibiting phosphorylation of AKT protein in the macrophage, so that the immune-related function of the macrophage under the stimulation of the cyst fluid is influenced, and the inhibitor can be used for preparing an anti-inflammatory drug for treating echinococcosis granulosus in a macrophage model (simulating the pathophysiological process of echinococcosis granulosus. The related pathological processes of the echinococcosis granulosa are intervened. The invention fills up the blank of developing a specific prevention and treatment preparation for echinococcosis granulosa by taking the macrophage UPF3B gene as an action target in the prior art.